Investors in Aquestive Therapeutics (NASDAQ:AQST) have unfortunately lost 36% over the last five years [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Aquestive Therapeutics, Inc. (AQST)
Last aquestive therapeutics, inc. earnings: 3/11 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.aquestive.com/investor-relations
Company Research
Source: Yahoo! Finance
NASDAQ:AQST ) shareholders for doubting their decision to hold, with the stock down 36% over a half decade. It's down 41% in about a quarter. Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns. Check out our latest analysis for Aquestive Therapeutics Given that Aquestive Therapeutics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually desire strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings. In the last five years Aquestive Therapeutics saw its revenue shrink by 2.4% per year. That's not what investors generally want to see. The share price decline at a rate of 6% per year is disappointing. But it doesn't surpr
Show less
Read more
Impact Snapshot
Event Time:
AQST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AQST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AQST alerts
High impacting Aquestive Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AQST
News
- Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and MetabolismGlobeNewswire
- Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $9.00 price target on the stock.MarketBeat
- Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows [Yahoo! Finance]Yahoo! Finance
- Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film [Yahoo! Finance]Yahoo! Finance
- Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual FilmGlobeNewswire
AQST
Earnings
- 5/7/24 - Miss
AQST
Sec Filings
- 6/21/24 - Form 8-K
- 6/21/24 - Form 4
- 6/21/24 - Form 4
- AQST's page on the SEC website